Indegene Limited IPO

Apply 0
Avoid 0

Indegene is a “digital-first” commercialization company focused exclusively on the global life sciences industry.

The solutions enable biopharmaceutical, emerging biotech and medical devices companies to develop products, launch them in the market, and drive sales through their life cycle in a more effective, efficient and modern manner.

Their portfolio of solutions cover all aspects of commercial, medical, regulatory and R&D operations of life sciences companies.

Life sciences enterprises require a talent pool with in-depth domain expertise on the journey of a drug or medical device from the research lab to the market to organise and analyse scientific and clinical data, navigate the regulatory landscape and the ethical guidelines within which the industry operates, and to develop the requisite medical content for healthcare professionals, patients, and payers.

Life sciences companies are embracing technological partners with the requisite domain expertise to aid them in this digital journey.

The Company is positioned at the intersection of healthcare and technology, The solutions span across different stages of the commercialization lifecycle of drugs and medical devices.

Competitive Strength

(i) Domain expertise in healthcare
(ii) Robust digital capabilities and in-house developed technology portfolio
(iii) Track record of establishing long-standing client relationships
(iv) Global delivery model
(v) Experienced management and motivated talent pool supported by marquee investors
(vi)  Track record of creating value through acquisitions

Objects of the Indegene Limited IPO:

The Offer comprises the Fresh Issue of Equity Shares aggregating up to ₹9,500 million by Company and the Offer for Sale of up to 36,291,497 Equity Shares by the Selling Shareholders. Company proposes to utilise the Net Proceeds towards funding of the following objects: 1. Repayment/prepayment of indebtedness of one of our Subsidiaries, ILSL Holdings, Inc. 2. Funding the capital expenditure requirements of our Company and our Material Subsidiary, Indegene, Inc. 3. Payment of consideration towards acquisition of additional shares in DT Associates Limited by ILSL Holdings, Inc., a Subsidiary. 4. General corporate purposes and inorganic growth.

Indegene Limited IPO Details:

Promoters And Management:

(i) Jairaj Manohar Purandare is a Non-Executive Independent Director on the Board of our Company. He holds a bachelor of science degree from the University of Bombay. He is a qualified chartered accountant. He has several years of experience in taxation. He was a member of the Central Direct Taxes Advisory Committee of the Government of India constituted in 2008. He was first appointed as a Director on the Board of our Company on April 28, 2022. (ii) Manish Gupta is the Chairman, Executive Director and the Chief Executive Officer of our Company. He holds a bachelor of technology degree in mechanical engineering from the Indian Institute of Technology (Banaras Hindu University), Varanasi and a post graduate diploma in management from the Indian Institute of Management, Ahmedabad. He has 22 years of experience in the technology-led healthcare solutions provider sector. He has been a Director of our Company since February 11, 2000. (iii) Dr. Sanjay Suresh Parikh is an Executive Director and Executive Vice President of our Company. He holds a bachelor of technology degree in electrical engineering from the Indian Institute of Technology, Bombay and a master of science degree (clinical engineering) from Case Western Reserve University, Ohio, USA. He also holds a doctorate in philosophy from Johns Hopkins University. He has 30 years of experience in the pharmaceuticals industry and technology-led healthcare solutions provider sector. He was appointed as a Director on the Board of our Company on January 29, 2002.

Financials of Indegene Limited IPO:

Particulares ( In Crore ) 2022 2021 2020
Revenue From Operations 1,664 966 642
Other Income 25 30 3
Revenue 1690 996 646
Employees Benefit Expenses 1,014 535 369
Other Expenses 363 200 129
EBITDA 312 261 147
Depreciation 33 25 19
EBIT 279 235 127
OPM (%) 18.50% 26.20% 22.76%
Finance Cost 5 6 8
PBT 226 231 75
Tax 63 45 26
PAT 164 145 -2
NPM (%) 9.74% 14.56% -0.43%
No. of Shares 22 22 22
EPS 7.4 6.5 -0.1

Comparison With Peers:

There is no listed peers in India.

Recommendation on Indegene Limited IPO:

To be updated once Indegene files for RHP.

Discussion on Indegene Limited IPO:

Leave a Reply